CN Mobile Logo


Head & Neck Cancer

Head & Neck Cancer

Immunotherapy treatment with nivolumab significantly improved survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.

Undergoing surveillance with PET/CT resulted in similar survival to planned neck dissection in patients with squamous cell carcinoma of the head and neck with nodal disease who have completed chemoradiotherapy.

The combination of radiation therapy plus cetuximab had higher rates of acute toxicity among patients with locally advanced squamous cell carcinoma of the head and neck compared with radiation therapy plus cisplatin.

Compared to the general population, the rate of suicide is three times more frequent among head and neck cancer patients, according to a retrospective study.

This article reviews the pathology and current evidence on systemic therapies for the management of advanced salivary gland cancers that are not amenable to local therapy.

The diversity and complexity, combined with the rarity of salivary gland malignancies, lead to definite and distinct challenges in their study, and consequently in advancing treatment options for affected patients.

Undergoing primary surgery may be the best treatment option for patients with advanced oropharyngeal and hypopharyngeal cancers.


Subscribe to Head & Neck Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.